Dermatology | Phase II Developments | UNITED STATES

Eirion Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

PHARMACEUTICAL MARKETING

Participation Not Confirmed

Update your events

Eirion Therapeutics Closes $40 Million Series A Investment and Licensing Deal with Shanghai Haohai Biological Technology Ltd.

Lead Product(s): Botulinum toxin type A

Therapeutic Area: Dermatology Product Name: ET-01

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Shanghai Haohai Biological Technology

Deal Size: $40.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing March 09, 2021

Details:

One license is for Eirion's neuromodulator-based product candidates, ET-01 and AI-09 for aesthetic indications; and a second license is for Eirion's small molecule product candidates, ET-02 and ET-03, which are intended for the treatment of hair loss and hair greying.

AnaptysBio

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

PHARMACEUTICAL MARKETING

Participation Not Confirmed

Update your events

Anaptysbio Reports Imsidolimab Poplar Phase 2 Clinical Trial in Moderate-To-Severe Palmoplantar Pustulosis Did Not Meet Primary Endpoint

Lead Product(s): Imsidolimab

Therapeutic Area: Dermatology Product Name: ANB019

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 08, 2021

Details:

Imsidolimab treatment did not demonstrate statistically significant improvement over placebo in PPPASI change from baseline at week 16 primary endpoint.

Dermata Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

PHARMACEUTICAL MARKETING

Participation Not Confirmed

Update your events

Dermata Therapeutics Presents Positive Data From its Phase 2b Clinical Study of DMT310 for the Treatment of Moderate to Severe Acne

Lead Product(s): DMT310

Therapeutic Area: Dermatology Product Name: DMT310

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 21, 2021

Details:

DMT310 once weekly treatment reduced both inflammatory and noninflammatory lesions and had a greater proportion of IGA treatment success in patients with moderate-to-severe acne. DMT310 was well tolerated, with no clinically relevant differences in the incidence of AEs.